We are able to recruit even rare trial populations fast and reliably.Our database is exclusive to people actively seeking to take part in clinical trials. This is a significant improvement over most databases of patients as these contain a majority of patients who are reluctant to participate in a clinical study.
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
-min.jpg)
.jpg)
